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Abstract
Lanthanum carbonate is used for treatment of hyperphosphatemia mostly in
patients with chronic renal failure. Although lanthanum carbonate is safe,
recently, lanthanum deposition in the gastrointestinal mucosa of patients has
been reported in the literature. This review provides an overview of
gastroduodenal lanthanum deposition and focuses on disease’s endoscopic,
radiological, and histological features, prevalence, and outcome, by reviewing
relevant clinical studies, case reports, and basic research findings, to better
understand the endoscopic manifestation of gastrointestinal lanthanum
deposition. The possible relationship between gastric lanthanum deposition
pattern and gastric mucosal atrophy is also illustrated; in patients without gastric
mucosal atrophy, gastric lanthanum deposition appears as diffuse white lesions
in the posterior wall and lesser curvature of the gastric body. In the gastric
mucosa with atrophy, lanthanum-related lesions likely appear as annular or
granular whitish lesions. Moreover, these white lesions are probably more
frequently observed in the lower part of the stomach, where intestinal metaplasia
begins.
Key words: Lanthanum carbonate; Hyperphosphatemia; Gastrointestinal endoscopy;
Lanthanum phosphate; Scanning electron microscopy; Energy-dispersive X-ray
spectrometry
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: This review provides an overview of the endoscopic and pathological diagnosis
of gastroduodenal lanthanum deposition. Previously reported case reports, case series,
and retrospective studies are reviewed, focusing on disease’s endoscopic, histological,
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and computed tomography features, prevalence, and outcome. Although gastroduodenal
deposition presents with white appearance at esophagogastroduodenoscopy, macroscopic
features and locations of gastric lesions possibly vary depending on the presence or
absence of mucosal atrophy. Our hypotheses are also related to the pattern of lanthanum
deposition in the gastric mucosa with/without atrophy, which will aid endoscopists to
understand this disease entity.
Citation: Iwamuro M, Urata H, Tanaka T, Okada H. Review of the diagnosis of




Lanthanum carbonate (Fosrenol®) is used for treatment of hyperphosphatemia and in
the management of  chronic  renal  failure,  especially in dialysis  patients[1-3].  Since
patients  with  chronic  renal  failure  generally  have  a  reduced  ability  to  excrete
phosphorus from the bloodstream, the levels of serum phosphorus increase as their
kidney  function  deteriorates,  resulting  in  hyperphosphatemia.  Persistent
hyperphosphatemia causes osteoporosis and deposition of calcium phosphate on the
blood vessel walls, leading to arteriosclerosis[4,5]. Moreover, hyperphosphatemia is
associated with an increased risk of cardiovascular events and mortality[6]. Therefore,
serum phosphorus levels should be controlled within their normal ranges during the
management of dialysis patients.
For the treatment of hyperphosphatemia in dialysis patients, aluminum-containing
agents have long been used as phosphate binders since the 1970s. However, chronic
administration of aluminum salts results in accumulation of aluminum in the central
nervous  system,  bone  and  hematopoietic  cells,  leading  to  encephalopathy,
osteomalacia, myopathy, and microcytic anemia[7]. Due to these severe toxic effects,
long-term use of aluminum salts is not allowed for dialysis patients. Alternatively,
calcium carbonate, calcium acetate, polymers such as sevelamer hydrochloride, and
lanthanum carbonate have been developed and used in clinical  practice.  Among
these,  calcium carbonate occasionally increases serum calcium levels  and causes
extraskeletal calcification. Sevelamer hydrochloride also exhibits adverse events such
as digestive symptoms mainly due to constipation. In contrast, lanthanum carbonate
has been widely used for patients with chronic renal failure because it is safe and
well-tolerated by the patients.
After ingestion of lanthanum carbonate, the lanthanum ion (La3+) is released in the
stomach and binds to dietary phosphate in the intestinal tract. Lanthanum phosphate
is an insoluble complex in the gut that is not absorbed by the digestive tract, thereby it
is  excreted from the body together with feces.  The absorption rate of lanthanum
carbonate from the gastrointestinal tract into the blood is less than 0.002%[8]. Because
the slightly  absorbed lanthanum is  reportedly excreted from the body via  bile[9],
lanthanum  carbonate  can  be  safely  used  even  in  patients  with  impaired  renal
function. Although absorbed lanthanum is known to deposit in the bones and liver,
the  amount  of  deposition  is  quite  small  and  does  not  cause  any  damage  to  the
organs[10,11].  However,  more  recently,  patients  with  lanthanum deposition in  the
gastrointestinal mucosa have been reported in the literature. Here, we review relevant
clinical studies, case reports, and basic research findings, including our articles, to




Hematoxylin and eosin staining of biopsy specimens containing lanthanum showed
deposition of fine, amorphous, eosinophilic material (Figure 1A). Deposited materials
have been variably described as inclusion-like materials with irregularly branching or
coiled  configurations[12],  granular,  brown material,  sometimes  needle-shaped or
crystalloid and irregular eosinophilic material with slit-like clefts[13,14], variably dense
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and granular deposits[15],  many colorless and coarse granular materials[16],  gray or
brown pigments or crystal-like structures[17], amphophilic and/or yellowish-brown
fine granules, and amphophilic and/or brownish rods or curly strings[18]. Deposited
materials are generally phagocytosed by macrophages in the lamina propria in the
s tomach  and  duodenum,  which  are  more  c lear ly  v i sua l ized  wi th
immunohistochemical staining, such as anti-CD68 staining (Figure 1B). Nakamura et
al[19] revealed that the macrophages are positive for both CD68 and CD206 staining
and speculated that  M2 macrophages  potentially  play  a  role  in  the  clearance  of
lanthanum from the gastroduodenal mucosa[19].
Diagnosis  of  lanthanum  deposition  can  be  made  with  (1)  conventional  light
microscopy  observation  of  the  fine,  amorphous,  eosinophilic  material;  and  (2)
medication information of  patient’s  current  or  past  use of  lanthanum carbonate.
Analysis of elements by energy-dispersive X-ray spectrometry (EDX) is not always
required,  unless  the  amount  of  lanthanum  deposition  is  subtle  or  pathological
features are atypical[20-24].
Electron microscopy observation
In scanning electron microscopy (SEM), deposited lanthanum is visible as bright areas
(Figure  2A).  Higher  magnification  shows  that  the  deposition  is  composed  of
aggregates  of  particles,  measuring  0.5–3  m  in  diameter  (Figure  2B).  Elemental
mapping by energy dispersive X-ray spectroscopy is useful to visualize distribution of
lanthanum (Figure 2C) and phosphate (Figure 2D), which is identical to that of the
bright areas. EDX also shows presence of lanthanum and phosphate elements (Figure
2E). Since both lanthanum and phosphate are generally detected simultaneously,
deposited material is considered as lanthanum phosphate. SEM observation and EDX
analysis enable analysis of the elemental composition and distribution of elements,
leading to direct  proof of  lanthanum deposition.  In contrast  to light microscopy,
deposited lanthanum is easily identified as bright areas with SEM[22].
COMPUTED TOMOGRAPHY FINDINGS OF LANTHANUM
DEPOSITION
Because  lanthanum  carbonate  is  not  transparent  to  X-rays,  it  has  a  radiopaque
appearance  in  plain  abdominal  radiography  and  computed  tomography  (CT)
scanning images[25]. Figure 3A shows ingested lanthanum carbonate in the stomach
(arrow) and colon (arrowhead) that is displayed as high-density substance. In this
patient, lanthanum carbonate and food contents are separated in the stomach, while
lanthanum carbonate in the colon is combined with digested materials and forms a
lump of feces. In another patient, deposited lanthanum in the stomach is observed as
a high-density layer within the gastric mucosa (Figure 3B). Namie et al[26] reported the
identification of a high-density layer in the stomach in 42 out of 70 (60%) patients
treated with lanthanum carbonate.
ENDOSCOPIC MANIFESTATION
Lanthanum deposition in the stomach
Lanthanum carbonate has been marketed as a phosphate binder since 2005 in United
States and was released in Japan in 2009. Despite its general tolerance and safety
profile, lanthanum deposition in the gastroduodenal mucosa of lanthanum carbonate
users was first reported in 2015. The endoscopic features of the gastric lesions were
initially portrayed as numerous small, irregular white spots[13], scattered ulcerations[15],
polyp, erosions, ulcer[12,14], white thickenings of annular shape or those on the gastric
folds[26],  slightly granular, white mucosa[20],  granular white depositions in reddish
mucosa[21], white spots[27], mucosal irregularity with reddish and/or whitish color, and
even nonremarkable mucosa[18]. Based on the accumulation of cases reported in the
literature and clinical  practice,  typical  endoscopic findings of  gastric  lanthanum
deposition have been currently recognized as white lesions.
In our earlier work, we reviewed four patients showing gastric white lesions (Bw)
and peripheral mucosa where the white substance was not endoscopically observed
(Bp) during biopsy[28]. We performed SEM analysis and EDX spectrometry to quantify
the lanthanum elements (wt%) in the biopsy specimens. We showed that the amount
of lanthanum was significantly higher in Bw than in Bp (0.15–0.31 wt% vs 0.00–0.13
wt%) (P  < 0.05), revealing that pathological lanthanum deposition coincides with
endoscopically observed white lesions in the gastric mucosa.  On the other hand,
although its deposited amount was small, lanthanum was detectable in EDX analysis
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Figure 1
Figure 1  Light microscopy images of gastric lanthanum deposition. A: Fine, amorphous, eosinophilic material is observed in hematoxylin and eosin staining; B:
Deposited material is generally phagocytosed by macrophages.
of the gastric mucosa where the white substance was not endoscopically visible[22,28].
Consequently,  a  subtle  amount  of  lanthanum  deposition  is  not  detected  under
endoscopic observation, while it can be detected with optical microscopy or electron
microscopy.
We  also  reviewed  gastric  lesions  of  lanthanum  deposition  and  subclassified
endoscopic  features  into  “whitish  spots”  (Figure  4A  and  B),  “annular  whitish
mucosa” (Figure  4C and D),  and “diffuse  whitish mucosa” (Figure  4E and F)[29].
Subsequently we added “fine granular  whitish deposition” as  a  new subtype of
endoscopic features (Figure 4G and H), because we noticed that whitish spots are
relatively infrequent compared with the other three subtypes, while small amount of
lanthanum deposition often appears as fine, granular white lesions[23]. We defined
annular whitish mucosa as a lesion (s) ≤ 20 mm in diameter with a white color in the
periphery. A diffuse whitish mucosa presents a white area > 20 mm in diameter,
where reddish areas may be intermixed. Fine granular whitish deposition is a tiny or
faint whitish lesion (s) ≤ 1 mm in diameter. Whitish spot is a whitish lesion ≤ 20 mm
in diameter with a uniform white color,  resembling gastric xanthoma. Generally,
diffuse whitish mucosa is observed in the non-atrophic mucosa of the gastric body,
whereas annular whitish mucosa and fine granular whitish deposition are observed in
the atrophic mucosa. In the following sections, we discuss endoscopic features of
lanthanum deposition focusing on gastric mucosal atrophy.
Lanthanum deposition in the atrophic gastric mucosa
Possible association with gastric lanthanum deposition and underlying regenerative
changes, intestinal metaplasia, and/or foveolar hyperplasia has been reported in 2015.
Makino et al[13] reported that macrophages containing lanthanum existed in the gastric
mucosa  with  atrophic  pyloric  glands  and foveolar  epithelium fully  replaced by
intestinal metaplasia. Tonooka et al[30] also found atrophic mucosa with metaplastic
epithelia in their patient. They speculated that altered mucosal structure resulted in
increased epithelial  permeability,  finally leading to lanthanum deposition in the
stomach. Ban et  al[18]  found a significant correlation between deposition grade of
lanthanum  and  mucosal  alterations  such  as  regenerative  changes,  intestinal
metaplasia, or foveolar hyperplasia, reinforcing the tendency of lanthanum deposition
in higher degree in the microscopically altered gastric mucosa. Ji et al[31] investigated
the mucosal barrier defects in patients with intestinal metaplasia using laser confocal
endomicroscopy. In vivo functional imaging revealed that lanthanum nitrate did not
permeated normal gastric epithelium, whereas it  permeated gastric mucosa with
intestinal metaplasia. These results indicated that gastric mucosa with regenerative
changes, intestinal metaplasia, and/or foveolar hyperplasia allows permeation of
lanthanum.
We recently reviewed endoscopic features of gastric lanthanum deposition in 10
patients with gastric atrophy (under review). Although gastric lanthanum deposition
appears as whitish lesions, this presentation was not observed in 1 out of 10 patients.
In the gastric mucosa with atrophy, the antrum (n = 5) and angle (n = 5) were most
frequently  involved  and  lanthanum deposition  presented  with  annular  and/or
granular whitish lesions. Whitish lesions were also found in the gastric body with
mucosal  atrophy that  appeared as  annular  (n  =  1),  granular  (n  =  1),  and diffuse
whitish  lesions  (n  =  1).  Consequently,  we speculate  that,  in  the  atrophic  gastric
mucosa, lanthanum-related lesions typically present with annular or granular whitish
lesions. In our earlier study, we investigated pathological features of four patients
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Figure 2
Figure 2  Electron microscopy analysis of gastric lanthanum deposition. A: In scanning electron microscopy,
deposited lanthanum is visible as bright areas; B: Deposited lanthanum is composed of aggregates of particles; C:
Elemental mapping with energy dispersive X-ray spectroscopy shows that the distribution of lanthanum; D:
Phosphate is identical to that of the bright areas; E: Energy dispersive X-ray spectroscopy shows presence of
lanthanum (La) and phosphate elements (P).
with annular whitish lesions[28]. We took one biopsy sample from white lesions and
the other sample from the surrounding mucosa approximately 5 mm away from the
white lesions. Intestinal metaplasia was identified in 3 out of 4 samples acquired from
the annular whitish lesion, whereas the surrounding mucosa contained no intestinal
metaplasia (Figure 5).  Thus,  we speculate that  lanthanum deposition appears as
“annular” or “granular” lesions in the atrophic mucosa, because intestinal metaplasia
unevenly exists in the background gastric mucosa and is susceptible to lanthanum
deposition.  In addition,  lanthanum-related lesions are probably more frequently
observed in the gastric antrum and angle, because intestinal metaplasia generally
appears at the lower part of the stomach.
We postulate that in the atrophic mucosa,  particularly in areas with intestinal
metaplasia, lanthanum deposition presents with annular and/or granular whitish
lesions, predominantly in the gastric antrum and angle. As the intestinal metaplasia
expands, the size of the areas with lanthanum deposition may increase (Figure 6A).
Lanthanum deposition in the gastric mucosa without atrophy
As  described  above,  several  reports  have  revealed  that  lanthanum  deposition
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Figure 3
Figure 3  Computed tomography images. A: Computed tomography scanning shows ingested lanthanum carbonate in the stomach (arrow) and colon (arrowhead)
as high-density substances; B: In another patient, deposited lanthanum in the stomach is observed as a high-density layer within the gastric mucosa (arrows).
develops  within  the  gastric  mucosa  showing  regenerative  changes,  intestinal
metaplasia, and/or foveolar hyperplasia. Because all these histopathological features
generally  arise  as  Helicobacter  pylori  (H.  pylori)-induced  mucosal  alterations,
lanthanum  deposition  had  been  considered  to  occur  in  the  stomach  in  close
association with H. pylori-infection. In contrast, we previously reported two patients
with  lanthanum  deposition  in  the  stomach  who  were  serologically  and
histopathologically negative for H. pylori[32]. In our patients, lanthanum deposition was
identified as diffuse whitish lesions, which were predominantly observed in the lesser
curvature and posterior wall of the gastric body, rather than in the antrum or angle.
Based on  this  observation,  we  hypothesized that  in  the  gastric  mucosa  without
atrophy, lanthanum primarily deposits in the lesser curvature and posterior wall of
the  gastric  body  and  presents  diffuse  whitish  lesions  (Figure  6B).  The  area  of
lanthanum deposition probably expands as time elapses unless the patient stops
lanthanum carbonate.
We speculate that gastric body-predominant lanthanum deposition occurs because
of the direct physical contact between ingested lanthanum carbonate and the gastric
body  mucosa [32].  Figure  3A  shows  a  CT  image  of  a  patient,  who  had  been
administered lanthanum carbonate. Even after abstinence from food and medicine for
10 h, a substantial amount of lanthanum was observed as a high-density substance
(Figure 3A, arrow),  predominantly in the gastric  body.  Thus,  the gastric  body is
expected to be involved in lanthanum deposition due to prolonged contact  with
ingested lanthanum.
Lanthanum deposition in the duodenum
Although several authors have described various endoscopic features of lanthanum-
related duodenal lesions as duodenal ulcer[12], granular and micronodular mucosa[33],
granular mucosa[34], and duodenitis[27], we first reported white villi as a characteristic
appearance of duodenal lanthanum deposition[35]. Subsequently, we retrospectively
reviewed endoscopic and pathological features in patients with pathologically proven
lanthanum deposition in the gastrointestinal tract[36].  We revealed that, among 19
patients who underwent biopsy from the duodenum, lanthanum deposition was
detected in 17 patients (89.5%). Moreover, white villi were observed in 15 patients
(88.2%). These results indicate that the duodenum is often involved in lanthanum
deposition,  which generally presents with white villi  (Figure 7).  However,  these
deposits may not be detected during esophagogastroduodenoscopy in some cases due
to the subtle degree of deposition. We consider that endoscopic biopsy should be
performed in the duodenum as well as in the stomach, regardless of the presence or
absence of white villi,  for accurate determination of lanthanum deposition in the
gastrointestinal tract[36].
Lanthanum deposition in other organs
Deposition  of  lanthanum in  organs  other  than  the  stomach  and duodenum has
scarcely been reported. In 2009, Davis et al[37]reported lanthanum deposition in the
mesenteric lymph nodes in postmortem examination of a dialysis patient. Yabuki et
al[17] and Tonooka et al[30] also described involvement of the gastric regional lymph
nodes in patients who underwent gastrectomy for gastric cancer. Goto et al[14] reported
lanthanum deposition in a tubular adenoma of the transverse colon.
In animal models, Lacour et al[38] investigated lanthanum concentrations in various
rat tissues after oral administration for 28 d. Although lanthanum concentration did
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Figure 4
Figure 4  Typical endoscopic features of gastric lanthanum deposition during conventional white-light (upper row) and magnified observation with narrow-
band imaging (lower row). A, B: “Whitish spot” is defined as a whitish lesion ≤ 20 mm in diameter with a uniform white color; C, D: “Annular whitish mucosa” are
lesion (s) ≤ 20 mm in diameter with white color in the periphery; E, F: “Diffuse whitish mucosa” appears with a white area > 20 mm in diameter; G, H: “Fine granular
whitish deposition” is a tiny or faint whitish lesion (s) ≤ 1 mm in diameter.
not increase in the brain and heart of rats, significantly elevated levels of lanthanum
concentration were observed in the liver,  lungs,  femur,  muscles,  and kidneys of
lanthanum-treated rats. Of note, compared with lanthanum-treated rats with normal
kidney function, rats with impaired kidney function showed significantly higher
tissue lanthanum concentration in the brain, liver, heart, lungs, femur, and muscles.
Therefore,  in  patients  with  chronic  kidney  disease,  a  long  period  of  careful
observation  may  be  required  to  reveal  organ-specific  properties  of  lanthanum
accumulation.
GASTRIC CANCER AND LANTHANUM DEPOSITION
Coexistence of gastric cancer and lanthanum deposition in the gastric mucosa has
been reported by several authors[13,17,30,39]. Makino et al[13] reported lanthanum-related
gastric lesions as numerous small, irregular white spots, which exist in the periphery
of the area with gastric cancer. Yabuki et al[17] also described lanthanum deposition in
non-neoplastic  area,  while  deposition  was  not  significant  in  the  gastric
adenocarcinoma lesion. The authors speculated that different permeability between
adenocarcinoma and background mucosa resulted in the uneven distribution of
lanthanum deposition. Tonooka et al[30]  and Takatsuna et al[39]  also described quite
small  amounts of lanthanum deposition in gastric cancer lesions.  Based on these
observations,  the  area  with  gastric  cancer  is  probably  spared  from  lanthanum
deposition.  Although understanding this  phenomenon will  help endoscopists  to
easily identify gastric cancer lesions in the lanthanum-deposited stomach, this concept
requires further investigation.
PREVALENCE
The actual prevalence of gastroduodenal lanthanum deposition among end-stage
renal disease patients treated with lanthanum carbonate has not yet been clarified.
Murakami et al[29] performed endoscopic biopsy in 9 out of 90 patients with lanthanum
carbonate prescription. Gastric lanthanum deposition was histologically diagnosed in
seven patients (7/9, 77.8%). Goto et al[14] reported that lanthanum was detected in the
stomach of 12 out of 14 patients who received lanthanum carbonate and underwent
endoscopic biopsy (12/14, 85.7%). Namie et al[26] found high-density lesions within the
gastric  mucosa  on CT scanning in  42  out  of  70  patients  who were  administered
lanthanum carbonate (42/70, 60.0%). Therefore, prevalence of lanthanum deposition
in the stomach is estimated to be 60%–85%. However, because only retrospective
studies have been performed, sampling biases are inevitable and prospective studies
are required to address this issue.
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Figure 5
Figure 5  Correlation between intestinal metaplasia and lanthanum deposition in the stomach. A: Esophagogastroduodenoscopy shows an annular whitish
lesion in the gastric antrum (white light observation); B: Esophagogastroduodenoscopy shows an annular whitish lesion in the gastric antrum (narrow-band imaging);
C, D: Biopsy sample acquired from a white lesion (A, B, arrows) contains intestinal metaplasia (C) and lanthanum deposition (D); E, F: In contrast, the sample
acquired from the surrounding mucosa approximately 5 mm away from the white lesions (A, arrowhead) contains no intestinal metaplasia (E) and lanthanum
deposition is subtle (F).
OUTCOME OF THE GASTRODUODENAL LANTHANUM
DEPOSITION
Our retrospective study revealed that, during continuous lanthanum carbonate use,
lanthanum-related lesions in the stomach were endoscopically unchanged in two
patients, whereas whitish lesions became apparent and spread in three patients[29],
indicating that gastric lanthanum deposition progresses in several patients in a time-
dependent manner. In contrast, Rothenberg et al[15] reported resolution of histiocytosis
in the stomach and significant decrease in the duodenum three months after cessation
of lanthanum carbonate in a patient with gastroduodenal lanthanum deposition.
However, Namie et al[26] reported that CT and pathological findings of lanthanum-
related  gastric  lesions  were  unchanged  eight  months  after  discontinuation  of
lanthanum  carbonate.  Awad  et  al[40]  also  noted  that  lanthanum-related  lesions
remained unchanged six months after drug cessation. Moreover, Hoda et al[33] detected
lanthanum deposition in a biopsy specimen from the stomach acquired seven years
after stopping lanthanum carbonate intake. It has not been clarified to date whether
lanthanum deposition in tissues is reversible or not.
The  pathological  significance  of  lanthanum deposition  in  the  gastrointestinal
mucosa  has  not  been  clarified,  and  there  is  no  consensus  on  whether  to  stop
administration of lanthanum carbonate in such cases. Yabuki et al[17]  investigated
histological changes in the gastric mucosa of lanthanum carbonate-consuming rats.
The authors  found a variety of  alterations including glandular  atrophy,  stromal
fibrosis,  proliferation of  mucous neck cells,  intestinal  metaplasia,  squamous cell
papilloma, erosion, and ulcer in the stomach of rats. They speculated that deposited
lanthanum was able to cause mucosal injury and abnormal cell proliferation, leading
to structural changes in the mucosa and neoplastic lesions in the stomach. In this
context,  we  consider  that  endoscopists  should  accurately  diagnose  lanthanum
deposition in the gastroduodenal tract in lanthanum-carbonate users and recommend
them to undergo regular endoscopy examinations in order to track progression of
white  lesions  and  elucidate  whether  lanthanum  deposition  is  related  to  health
problems.
CONCLUSION
Lanthanum deposition in the stomach and duodenum is recognized as whitish lesions
during endoscopy examination. Accurate diagnosis and keeping track of the health of
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Figure 6
Figure 6  Hypothesis regarding the pattern of lanthanum deposition in the gastric mucosa with or without
atrophy. A: In the atrophic mucosa, particularly in areas with intestinal metaplasia, lanthanum deposition probably
presents with annular and/or granular white lesions, predominantly in the gastric antrum and angle. As intestinal
metaplasia expands, the size of the areas with lanthanum deposition may increase; B: In the gastric mucosa without
atrophy, lanthanum primarily deposits in the lesser curvature and posterior wall of the gastric body and presents
diffuse whitish lesions. The area of lanthanum deposition probably expands as time elapses unless the patient stops
lanthanum carbonate.
patients  with  gastroduodenal  lanthanum  deposition  are  essential  to  elucidate
pathogenicity of lanthanum deposition in the gastrointestinal tract.
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Figure 7
Figure 7  Endoscopic images of the duodenal lanthanum deposition. A: A lanthanum-related lesion in the duodenum presents with white mucosa; B: Magnified
image with narrow-band imaging shows white depositions within the duodenal villi.
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